Hasil Pencarian - Claes Held

Perbaiki Hasil
  1. 1
    When do we need clinical endpoint adjudication in clinical trials?

    When do we need clinical endpoint adjudication in clinical trials? oleh Claes Held

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Predicting two-year survival versus non-survival after first myocardial infarction using machine learning and Swedish national register data

    Predicting two-year survival versus non-survival after first myocardial infarction using machine learning and Swedish national register data oleh John Wallert, Mattia Tomasoni, Guy Madison, Claes Held

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The factor structure of the cardiac anxiety questionnaire, and validation in a post-MI population

    The factor structure of the cardiac anxiety questionnaire, and validation in a post-MI population oleh Philip Leissner, Claes Held, Elisabet Rondung, Erik M. G. Olsson

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study.

    Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study. oleh Christina Christersson, Claes Held, Angelo Modica, Johan Westerbergh, Gorav Batra

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Thromboembolic and bleeding events after valvular intervention in patients with atrial fibrillation

    Thromboembolic and bleeding events after valvular intervention in patients with atrial fibrillation oleh Johan Westerbergh, Christina Christersson, Gorav Batra, Claes Held, Ebba-Louise Skogseid

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Clinical Outcomes in Patients With Atrial Fibrillation Treated With Non–Vitamin K Oral Anticoagulants Across Varying Body Mass Index

    Clinical Outcomes in Patients With Atrial Fibrillation Treated With Non–Vitamin K Oral Anticoagulants Across Varying Body Mass Index oleh Astrid Fritz Hansson, Karin Jensevik Eriksson, Christina Christersson, Claes Held, Gorav Batra

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease

    Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease oleh Anders Larsson, Christina Christersson, Gorav Batra, Claes Held, Henrik Renlund, Angelo Modica

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Major bleeding in patients with atrial fibrillation treated with apixaban versus warfarin in combination with amiodarone: nationwide cohort study

    Major bleeding in patients with atrial fibrillation treated with apixaban versus warfarin in combination with amiodarone: nationwide cohort study oleh Christina Christersson, Gorav Batra, Claes Held, Henrik Renlund, Angelo Modica, Astrid Fritz Hansson

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

    Serum Neurofilament Light Chain in Patients With Atrial Fibrillation oleh Karl Sjölin, Julia Aulin, Lars Wallentin, Niclas Eriksson, Claes Held, Kim Kultima, Jonas Oldgren, Joachim Burman

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    The effect of group-based cognitive behavioral therapy on inflammatory biomarkers in patients with coronary heart disease—results from the SUPRIM-trial

    The effect of group-based cognitive behavioral therapy on inflammatory biomarkers in patients with coronary heart disease—results from the SUPRIM-trial oleh Erik M. G. Olsson, Fredrika Norlund, Ronnie Pingel, Gunilla Burell, Mats Gulliksson, Anders Larsson, Bo Karlsson, Kurt Svärdsudd, Claes Held

    Diterbitkan 2018-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy

    Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy oleh Claes Held, Nermin Hadziosmanovic, Philip E. Aylward, Emil Hagström, Judith S. Hochman, Ralph A. H. Stewart, Harvey D. White, Lars Wallentin

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Reducing stress and anxiety in patients with myocardial infarction with non-obstructive coronary arteries or Takotsubo syndrome: A non-randomized feasibility study

    Reducing stress and anxiety in patients with myocardial infarction with non-obstructive coronary arteries or Takotsubo syndrome: A non-randomized feasibility study oleh Elisabet Rondung, Sophia Monica Humphries, Erik Martin Gustaf Olsson, Runa Sundelin, Fredrika Norlund, Claes Held, Jonas Spaak, Per Tornvall, Patrik Lyngå

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21).

    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21). oleh Agneta Siegbahn, Niclas Eriksson, Erika Assarsson, Martin Lundberg, Andrea Ballagi, Claes Held, Ralph A H Stewart, Harvey D White, Mikael Åberg, Lars Wallentin

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)

    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21) oleh Agneta Siegbahn, Niclas Eriksson, Erika Assarsson, Martin Lundberg, Andrea Ballagi, Claes Held, Ralph A. H. Stewart, Harvey D. White, Mikael Åberg, Lars Wallentin

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease

    Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease oleh Ralph A. H. Stewart, Claes Held, Sue Krug‐Gourley, Dawn Waterworth, Amanda Stebbins, Karen Chiswell, Emil Hagstrom, Paul W. Armstrong, Lars Wallentin, Harvey White

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    The e-mental health treatment in Stockholm myocardial infarction with non-obstructive coronaries or Takotsubo syndrome study (E-SMINC): a study protocol for a randomised controlled trial

    The e-mental health treatment in Stockholm myocardial infarction with non-obstructive coronaries or Takotsubo syndrome study (E-SMINC): a study protocol for a randomised controlled... oleh Erik M. G. Olsson, Fredrika Norlund, Elisabet Rondung, Sophia M. Humphries, Claes Held, Patrik Lyngå, Jonas Spaak, Örjan Sundin, Runa Sundelin, Philip Leissner, Lena Kövamees, Per Tornvall

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy

    Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy oleh Mika Hilvo, Lars Wallentin, Tatevik Ghukasyan Lakic, Claes Held, Dimple Kauhanen, Antti Jylhä, Johan Lindbäck, Agneta Siegbahn, Christopher B. Granger, Wolfgang Koenig, Ralph A. H. Stewart, Harvey White, Reijo Laaksonen

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study.

    Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. oleh Lars Wallentin, Niclas Eriksson, Maciej Olszowka, Tanja B Grammer, Emil Hagström, Claes Held, Marcus E Kleber, Wolfgang Koenig, Winfried März, Ralph A H Stewart, Harvey D White, Mikael Åberg, Agneta Siegbahn

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

    Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque... oleh Claes Held, Harvey D. White, Ralph A. H. Stewart, Andrzej Budaj, Christopher P. Cannon, Judith S. Hochman, Wolfgang Koenig, Agneta Siegbahn, Philippe Gabriel Steg, Joseph Soffer, W. Douglas Weaver, Ollie Östlund, Lars Wallentin

    Diterbitkan 2017-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial

    Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial oleh Gilles R. Dagenais, Hyejung Jung, Eva Lonn, Peter M. Bogaty, Mahshid Dehghan, Claes Held, Alvaro Avezum, Petr Jansky, Matyàs Keltai, Lawrence A. Leiter, Patricio Lopez‐Jaramillo, William D. Toff, Jackie Bosch, Salim Yusuf

    Diterbitkan 2018-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: